December 11, 2024 4:46pm

Sentiment couldn’t be struck faster from the visit of “uncle algo and his trading dwarfs”

it’s not hard to be right so often, it’s about defining insight and dissecting sentiment

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

Invest like you're driving on an icy, windy road, not an open highway.

 

RegMed Investors’ (RMi) pre-open: more econs … https://www.regmedinvestors.com/articles/13730

 

Wednesday: The Dow closed DOWN -99.27 points or -0.22%, the S&P closed UP +49.28 points or +0.82% while the Nasdaq closed UP +347.65 points or +1.77%

  • Indexes closed mixed Wednesday from a losing day in the prior session
  •  The Nasdaq surged Wednesday after November’s inflation report met economists’ projections, clearing the way for the Fed to cut interest rates again at its December meeting next week

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • November’s consumer price index, which tracks a basket of goods and services, was in line with expectations. The reading showed a +0.3% rise from October and +2.7% increase from a year ago. Excluding volatile food and energy prices, core CPI increased +0.3% on the month and +3.3% on an annual basis

Wednesday’s advance/decline line at the open was negative with 12 incliners, 21 declined and 2 flats; ending with a negative close at the close of 8 incliner, 25 decliners and 2 flats

  • The sentiment and sector churn continues

Metrics:  Wednesday, the IBB was down -0.46%, the XBI was down -0.45% while the VIX was down -0.60 points or -4.23% at 13.58

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”: 

Q4/24 – 2 positive and 6 negative closes

•              November – 1 holiday, 10 negative and 10 positive closes           

•              October: 8 positive and 15 negative sessions

 

Wednesday’s Closing Down (10 of 25):

  • Beam Therapeutics (BEAM -$1.30 after Tuesday’s +$2.69 after Monday’s +$0.81),
  • Lenz Therapeutics (LENZ -$0.94 after Tuesday’s +$0.86 after Monday’s -$3.85),
  • Blueprint Medicine (BPMC -$0.92 after Tuesday’s+$0.82 after Monday’s -$1.40),
  • CRISPR Therapeutics (CRSP -$0.90 after Tuesday’s -$1.16 after Monday’s -$2.49),
  • Mesoblast (MESO -$0.77 after Tuesday’s +$0.36 after Monday’s -$0.26),
  • Intellia Therapeutics (NTLA -$0.62 after Tuesday’s +$0.10 after Monday’s -$0.10),
  • Regenxbio (RGNX -$0.46 after Tuesday’s -$0.41 after Monday’s +$0.59),
  • Verve Therapeutics (VERV -$0.42 after Tuesday’s -$0.47 after Monday’s +$0.72),
  • MiMedx (MDXG -$0.29 after Tuesday’s +$0.18 after Monday’s -$0.11),
  • Ionis Pharmaceuticals (IONS -$0.27 after Tuesday’s -$0.32 after Monday’s +$0.47),

Flat (2)

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Wednesday’s Closing Up (8 of 8):

  • Moderna (MRNA +$1.36 after Tuesday’s -$4.14 after Monday’s +$1.21)
  • Vericel VCEL +$0.36 after Tuesday’s +$1.20),
  • uniQure NV (QURE +$0.35 after Tuesday’s +$8.01 after Monday’s -$0.15),
  • Sage Therapeutics (SAGE +$0.32),
  • Alnylam Pharmaceuticals (ALNY +$0.24 after Tuesday’s -$1.98 after Monday’s -$0.37),
  • Voyager Therapeutics (VYGR +$0.15 after Tuesday’s -$0.18 after Monday’s -$0.08)
  • BioLife Solutions (BLFS +$0.12),
  • Adverum Biotechnologies (ADVM +$0.04),
  • AxoGen (AXGN +$0.02 after Tuesday’s +$0.17 after Monday’s -$0.24),

 

The BOTTOM LINE: “close the back door” … slang

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

The cell and gene therapy sector stocks kicked off December, the final month of 2024 with

  • A new week, starts with 3 negative closes
  • A Monday positive followed by Thursday and Wednesday, Tuesday’s negative closes and Friday positive close

While the Dow closed in negative territory for the 3rd session, the S&P 500 closed Wednesday higher with the Nasdaq rose by over 1.7% and crossed above 20,000 for the 1st time.

  • November's Consumer Price Index (CPI) print is in focus, showing a 0.3% rise month-over-month and 2.7% year-over-year.

 

December is traditionally a good month for stocks, yet I see the sector range-bound and taking some hits into the end of 2024.

  • Never forget end of year tax selling and portfolio rotation due to recommendations are a’comin’!
  • Portfolio managers are addressing rotations as year comes to years-end.
  • I keep writing about uncertainty and skepticism … and coming realities.
  • Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even after sector earnings kicked the bucket down the road!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:    

  • Wednesday: Moderna (MRNA), Vericel (VCEL) and uniQure NV (QURE)
  • Tuesday: uniQure NV (QURE), Beam Therapeutics (BEAM) and Blueprint Medicine (BPMC)
  • Monday: Moderna (MRNA), Verve Therapeutics (VERV) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Wednesday: Beam Therapeutics (BEAM), Lenz Therapeutics (LENZ) and Blueprint Medicine (BPMC)
  • Tuesday: Moderna (MRNA), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP)
  • Monday: Lenz Therapeutics (LENZ), CRISPR Therapeutics (CRSP) and Blueprint Medicine (BPMC)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.